Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation
Portfolio Pulse from Vandana Singh
JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ:VIGL) with a Market Outperform rating and a price target of 23. The analysts note that the company's focus on neurodegenerative diseases and its lead development candidate, VGL101, can reduce translational development risk and increase the clinical probability of success. The addressable ALSP opportunity is attractive with JMP projecting peak sales of around $1.1 billion in 2031.
October 18, 2023 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has initiated coverage on Vigil Neuroscience with a Market Outperform rating and a price target of 23. The company's focus on neurodegenerative diseases and its lead candidate VGL101 could reduce risk and increase success.
The positive coverage from JMP Securities, along with the promising outlook for the company's lead candidate VGL101, could potentially drive the stock price up in the short term. However, the actual impact will depend on the market's reception of this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100